Background
Breast cancer (BC) is the most frequent malignancy in women with 800 cases out of 100,000 people, four-times as many as the second most frequent one, i.e. colorectal cancer [
1]. Histopathology classification of BC according to tumor grade, stage, histotype, lymph node invasion and hormonal receptor status [
2] is broadly used to draw correlations with survival. However, this classification performs poorly in predicting differential biological aggressiveness of tumors with identical grade and stage. As an example, patients with the best prognosis, i.e. bearing small size tumors, expressing estrogen receptors and without lymph node invasion, experience early tumor relapse in 10-20 % of the cases [
3,
4]. Cases that relapse do not detectably differ from those that do not, as far as conventional prognostic parameters are concerned.
Determinants of tumor biological history are expected to add to traditional prognostic classification algorithms [
5,
6]. Individual oncogenic determinants, e.g. p53, Her-2, E-cadherin, BRCA-1, Trops, have indeed been shown to add to prognostic and predictive procedures [
5,
7‐
11]. However, they largely failed to outperform traditional prognostic indicators.
Tumor development depends on the accumulation of several specific genetic and epi-genetic changes [
12‐
14]. Thus, the analysis of individual oncogenic factors is unlikely to suffice in defining the biological nature and aggressiveness of a tumor [
15]. Major control pathways or clusters of drivers of cell growth, apoptosis or invasion are, on the other hand, expected to associate with tumor aggressiveness and overall malignancy much more strongly than individual factors. In this work we went on to test this model. Histopathology and oncogenically-activated determinants of tumor progression of BC were analyzed in the framework of a case-control study. The results obtained were evaluated by means of statistical analyses able to detect significant interactions of biological determinants connected with tumor relapse. This showed that correlated p53, Bcl-2 and cathepsin D specifically associate with unprecedented high levels of relative risk for local invasion and metastatic relapse. As matrix metalloproteases, which play a key role in local invasion and distant cancer spreading, were shown to be a transactivation target for mutant p53, in cooperation with oncogenic Ras, exon sequence analysis was performed for
TP53 and
RAS genes, and findings were coordinately analyzed with the immunohistochemistry (IHC) data and clinical phenotypes.
Discussion
Traditional prognostic indicators of BC, i.e. lymph node diffusion, tumor size, grading and estrogen receptor expression, are inadequate predictors of metastatic relapse. Therefore, identification of additional parameters versus traditional prognostic indicators is urgently needed. Several genes (oncogenes, tumor suppressor genes, transcription factors, signaling molecules, adhesion proteins, proteases) play a driving role in tumor progression [
52]. Individual oncogenic determinants, e.g. p53, Her-2, E-cadherin, Trops, have been shown to possess prognostic/predictive power [
7‐
11,
20,
53]. However, they did not outperform traditional prognostic indicators. Tumor progression is a multistep process [
13,
54‐
58], which correlates with multiple, successive molecular modifications [
13,
14]. Hence, clusters of tumor-driving traits are expected to be associated with tumor aggressiveness and overall malignancy, much more strongly than individual factors. In this work, we tested such a model in BC. Histopathological and molecular determinants of tumor progression of post-menopausal BC were analyzed, to assess impact on metastatic relapse. Aggregation of cancer determinants was expolored by modeling through discriminant analysis, logistic regression, partial least squares and partition trees. This identified upregulation of p53 and cathepsin D, together with downregulation of Bcl-2, as associated with a major increase in risk of disease relapse.
p53 is a tumor suppressor gene which is frequently mutated in cancer cells [
59], and was identified as an indicator of both prognosis [
8,
60‐
62] and response to therapy [
7]. A cooperation of p53 with other drivers of tumor progression, e.g. Her-2 [
8,
63] and Trop-1/Ep-CAM [
10,
64] was previously shown, thus lending support our model of interaction between distinct prognostic determinants.
Bcl-2 inhibits cellular apoptosis [
65]. Hower, Bcl-2 expression has a stronger impact as indicator of retained cancer differentiation, and of better disease outcome [
45]. Indeed, loss of Bcl-2 was shown to have negative prognostic impact [
46,
47,
49]. Bcl-2 expression was lost in 70 % of the most aggressive triple-negative BC cases, i.e. those lacking ERα, PgR and Her-2, and was significantly associated with high proliferation, tumor progression and increased risk of death and recurrence [
48]. Supporting these findings, we found that Bcl-2 expression negatively correlated with cancer grading and with the expression of p53, cyclin E and Her-2. On the other hand, Bcl-2 expression was found to correlate with that of ERα and PgR, i.e. with differentiated cancer phenotypes.
Proteases, e.g. cathepsin D, uPA, MMP-11, are secreted by transformed or stromal cells of BC, and impact on tumor invasion and mestastasis [
66‐
76]. uPA is modulated by the plasminogen activator inhibitor-1 (PAI-1), and combined assessment of uPA and PAI-1 was shown to be of value for prognostic determination [
77,
78], indicating an impact of overall proteolytic balance on tumor progression. As indicated above for loss of Bcl-2, triple-negative BC were frequently associated with overexpression of cathepsin-D, and with aggressive disease course through lymph node invasion and high cancer cell proliferation/Ki-67 index [
79].
As for the additional determinants we analyzed, cyclins D and E regulate the cell cycle [
80], and increased levels are associated with worse prognosis and increased relapse rates in BC patients [
81]. p27/kip1 and p16/INK4 are inhibitors of cyclin-dependent kinases and can prevent progression through the cell cycle [
55], but can also be determinants of malignancy. High levels of the p27/kip1 cyclin inhibitor have been associated with worse prognosis and higher relapse rate in BC [
82,
83]. On the other hand, deletion of p16/INK4 can be selected for in BC [
84]. Consistent with an interactive predictive value, the levels of Cyclin E and of the p27 cyclin inhibitor were shown to have a higher impact when combined [
82]. The mitotic index (Ki-67) is a measure of the percentage of tumor cells in active division and is a relevant prognostic indicator in BC [
31]. Her-2 is a transmembrane tyrosine kinase receptor that regulates the growth of tumor cells [
85]. The levels of expression of Her-2 have been shown to be independent indicators of worse prognosis, with respect to tumor relapse and overall survival in BC patients [
86].
To identify interaction effects of different variables on disease outcome, expression profiles of tumor progression drivers were assessed, and results were evaluated by means of statistical analyses designed to detect significant prognostic interaction. To preempt the need for a priori specified hypotheses, patterns of aggregation of molecular parameters affecting prognosis were modeled through logistic regression and PLS-DA, using relapse as a dichotomic variable. PLS-DA score plot clustering of tumor samples with or without disease relapse, obtained separation between the two clusters. Major discriminant parameters were shown to be, HER-2, p53, p16, Cyclin E, PgR, together with stromal cathepsin D, PAI-1, uPA and MMP-11 were found to markedly contribute to the classification model; these efficiently clustered with local relapse, lymph node diffusion, tumor staging and grading. Among prognostic factors, p53 and cathepsin D stood up as major determinants of cancer relapse. Bcl-2 expression was shown to provide with unprecedented protective power versus tumor recurrence, candidating the combined assessment of these IHC parameters for use in clinical settings. Of interest, our case-control study included only one triple negative BC, indicating that a triple negative status was not a confounding variable in our study, and that p53, cathepsin D and Bcl-2 are efficient aggressiveness determinants in BC across currently categorized cancer subgroups.
Specific mutations of oncogenes and tumor suppressor genes play key roles in tumor progression.
TP53 is frequently inactivated in several human tumors [
87‐
89] and
TP53 mutations help classifying and selecting patient subgroups with different biological features [
8,
90], particularly in BC [
8,
10,
31]. Mutations in different regions of
TP53 were shown to be heterogenous in nature [
91] and clinical outcome, indels having the highest impact [
92]. Consistent, sequencing of the
TP53 gene revealed a subgroup of BC where truncating mutations, such as indels and stop codons, were in all cases associated with cancer relapse.
The
RAS genes code for small G proteins that play a critical role in signal transduction pathways downstream of growth-factor receptors.
RAS mutations can affect prognosis [
93‐
95]. Moreover, Ras downstream target genes are synergistically upregulated by mutated p53 and Ha-Ras, among them, matrix metalloproteases, which play a key role in local invasion and distant dissemination [
96]. Hence, hot-spot sequence analysis was performed for
Ha-and
Ki-RAS, and findings were correlated with the IHC data and clinical phenotypes. The constitutive activation of the Ras proteins by point mutations, concentrated in hotspots at codons 12, 13, 61, is among the most frequently observed oncogene activation in human malignancies (75 % of adenocarcinomas of the pancreas, 40 % of adenomas and carcinomas of the colon and rectum, 25 % of carcinomas of the lung) and have been linked to worse prognosis [
97]. However, although mutations in Ha-
RAS and of Ki-
RAS are often found in animal models of BC [
98], their mutation frequency in human BC was shown to vary widely across studies. c-Ki-
RAS mutations were shown to occur in 1 out of 8 BC by Yanez et al. [
99].
Ha-
RAS mutations were detected by Spandidos et al. [
100], but not by Biunno et al. [
101]. An overall low frequency of
Ha-
RAS mutations was found in most subsequent studies [
97,
102‐
106]. Our findings support an incidence of mutated
Ha-RAS in ≈ 5 % of BC cases. No mutations were detected in
Ki-RAS. Remakably, all
RAS mutations were identified in relapsed cases, suggesting impact of mutated
Ha-RAS in a distinct subset of malignant BC [
97,
104‐
106]. This finding warrants testing in a prospective clinical trial with adequate size and predictive power for relapsed cases subgroup dissection.